Literature DB >> 10477216

Contra-indications to metformin therapy are largely disregarded.

A Holstein1, D Nahrwold, S Hinze, E H Egberts.   

Abstract

AIMS: To investigate the current metformin treatment practice and in particular to examine the consideration given to its contraindications.
METHODS: A cross-sectional analysis of 308 consecutive Type 2 diabetic patients (mean age 66+/-11.3 years) previously treated with metformin on an outpatient basis and admitted to a German general hospital during the period from 1 January 1995 to 31 May 1998 because of acute disease or in order to optimize their diabetes management. All patients underwent a basic investigation comprising a documentation of their medical history, a physical examination, an electrocardiogram, and an extensive laboratory profile; 34% also had acute coronary angiography.
RESULTS: On admission to hospital, 73% of the patients were found to have contra-indications, risk factors, or intercurrent illnesses necessitating discontinuation of metformin; 51% of these patients had several of these conditions. As major contra-indications to metformin, renal impairment was present in 19% of all patients, heart failure in 25%, respiratory insufficiency in 6.5%, and hepatic impairment in 1.3%. The risk factors to metformin included advanced coronary heart disease in 51%, atrial fibrillation in 9.8%, chronic alcohol abuse in 3.3%, advanced peripheral vascular disease in 2%, and pregnancy in 0.7%. As intercurrent illnesses, cerebral ischaemia occurred in 9.8% under metformin treatment and malignancies were diagnosed in 6.5%. The patients with contra-indications or requiring caution to metformin were significantly older and had previously been treated with more cardiovascular medication than those without such reservations (P<0.001).
CONCLUSIONS: Despite the considerable risk of lactic acidosis in the majority of patients, no cases were observed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10477216     DOI: 10.1046/j.1464-5491.1999.00115.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  28 in total

1.  Clinical pharmacology physiology conference: metformin and lactic acidosis (LA).

Authors:  Chadi Alkhalil; George Zavros; Fadi Bailony; David T Lowenthal
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 2.  Metformin's contraindications should be contraindicated.

Authors:  James McCormack; Kevin Johns; Hugh Tildesley
Journal:  CMAJ       Date:  2005-08-30       Impact factor: 8.262

Review 3.  Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Authors:  Silvio E Inzucchi; Kasia J Lipska; Helen Mayo; Clifford J Bailey; Darren K McGuire
Journal:  JAMA       Date:  2014 Dec 24-31       Impact factor: 56.272

Review 4.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.

Authors:  Dean T Eurich; Finlay A McAlister; David F Blackburn; Sumit R Majumdar; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson
Journal:  BMJ       Date:  2007-08-30

5.  Metformin in peritoneal dialysis: a pilot experience.

Authors:  Abdulla Khalaf Al-Hwiesh; Ibrahiem Saeed Abdul-Rahman; Mohammad Ahmad Nasr El-Deen; Emmanuel Larbi; Jose C Divino-Filho; Fahd Abdul-Aziz Al-Mohanna; Krishan L Gupta
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

6.  The Association between Metformin Therapy and Lactic Acidosis.

Authors:  Isabelle H S Kuan; Ruth L Savage; Stephen B Duffull; Robert J Walker; Daniel F B Wright
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

Review 7.  Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?

Authors:  A A Tahrani; G I Varughese; J H Scarpello; F W F Hanna
Journal:  BMJ       Date:  2007-09-08

8.  [Female patient with type 2 diabetes in coma with metabolic acidosis].

Authors:  T zur Nieden; T Conrad
Journal:  Internist (Berl)       Date:  2009-11       Impact factor: 0.743

9.  Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.

Authors:  P D Home; S E Kahn; N P Jones; D Noronha; H Beck-Nielsen; G Viberti
Journal:  Diabetologia       Date:  2010-06-08       Impact factor: 10.122

10.  Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality.

Authors:  Dean T Eurich; Ross T Tsuyuki; Sumit R Majumdar; Finlay A McAlister; Richard Lewanczuk; Marcelo C Shibata; Jeffrey A Johnson
Journal:  Trials       Date:  2009-02-09       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.